ENO2 and bone metastasis: In univariate analyses, the lower BMI of patients, higher CEA and NSE level before treatment, liver metastasis, bone metastasis, and retroperitoneal lymph node (LN) metastasis were associated with increased risks of acquired T790M mutation.